BCL-2 Inhibitors
1 drugsAbout BCL-2
BCL-2, or B-cell lymphoma 2, is a protein that regulates programmed cell death (apoptosis), functioning as an anti-apoptotic protein to prevent cell self-destruction. Its role in cell survival makes it a significant target for drug development, particularly where uncontrolled cell proliferation occurs.
While there is currently no genetic evidence directly linking BCL-2 to specific diseases, its role in preventing apoptosis has made it a target for cancer therapy. Inhibiting BCL-2 can induce apoptosis in cancer cells, providing a therapeutic benefit.
The therapeutic potential of BCL-2 is validated by VENCLEXTA (AbbVie), the only approved drug with 3 indications. It is a small molecule and the first drug was approved in 2016.
Top BCL-2 Drugs
AbbVie is the only company with an approved BCL-2 targeting drug.
The market is highly concentrated, suggesting high barriers to entry or untapped potential.
BCL-2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BCL-2, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation.
BCL-2 Clinical Trials 633 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BCL-2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 280 | 64 | 69 | 141 | 48% |
| Phase 2 | 287 | 38 | 30 | 219 | 56% |
| Phase 3 | 60 | 14 | 4 | 42 | 78% |
| Phase 4 | 6 | 1 | 0 | 5 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved BCL-2 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BCL-2. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
BCL-2 Drug Approval Timeline (2016 - 2016)
The first and only BCL-2 targeting drug was approved in 2016.
The approval timeline suggests the field is still early, with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 232 (72 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BCL-2. A trial counts if an approved drug acting on BCL-2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.